(ATNM) Comes Out Firing To New 52-Week High (Breaking News)
ATNM needs full attention once again this week.
Another big press release was just dropped by the company. Check it out:
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination Trial
- 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches
- Patients on study received a median of 2 lines of prior therapy with 57% receiving prior treatment with venetoclax and 67% had adverse cytogenetics with 52% of patients having a TP53 mutation
- Data accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Symposium on Saturday, December 10th at 10:30 AM CT
NEW YORK, Nov. 3, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today highlighted positive results from the Phase 1 trial evaluating Actimab-A with salvage chemotherapy regimen CLAG-M in fit patients with relapsed or refractory acute myeloid leukemia (AML) that is being conducted at the Medical College of Wisconsin as investigator sponsored study. These data were detailed in an abstract accepted for oral presentation at the 64th Annual ASH Meeting & Symposium being held December 10-13, 2022 in New Orleans, Louisiana.
Read the full article here.
With this news, ATNM is off to a solid green start today and just reached a new 52-week high of $15.02. Make sure to keep a close eye on it.
Plus don't forget this announcement from earlier this week. H.C. Wainwright raised their already massive ATNM price target from $45 to $53.
Drop everything and get ATNM on radar now.
ATNM needs to be back on radar Thursday and here's why.
This week, the company dropped two major announcements.
First, there was this: Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Dr. Avinash Desai, Actinium's Chief Medical Officer, shared, "We are excited that the randomized, controlled, multi-center, pivotal SIERRA trial has delivered these results for patients that need new treatment options. Our goal is to increase access to BMT and improve patient outcomes with Iomab-B, and these topline results move us in this direction given their statistical significance..."
Second, the company announced this: Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
On the heels of the first announcement this week, H.C. Wainwright raised their already massive price target from $45 to $53.
Even better, Barchart is reporting multiple triggered technicals over the short, medium, and long term for ATNM.
In fact, 13 technical indicators are triggered overall over at Barchart.
It's a lot to take in for sure, but it's important to do it quickly and get ATNM back on radar this second.
Take a moment now and read my initial ATNM report below.
*Actinium Pharmaceuticals, Inc. (ATNM)*
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs.
And ATNM has 4 potential catalysts to pay attention to right now. Check them out:
No. 1 - Bullish Triggered Technicals Galore
No. 2 - Low Float Volatility Possible On Daily Basis
No. 3 - Cantor Fitzgerald Initiates Coverage With $20 Target
No. 4 - Company Update Presents A Possibly Mind-Blowing Q4
But more on those in a second...
There is Demand For a Leukemia Cure... and the Market Looks Lucrative
The leukemia therapeutics market could reach $17.1Bn by 2024 from $12.3Bn in 2019, at a CAGR of 6.8%.